Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 29 11:36AM ET
4.15
Dollar change
-0.19
Percentage change
-4.38
%
IndexRUT P/E- EPS (ttm)-0.38 Insider Own6.67% Shs Outstand62.07M Perf Week-2.58%
Market Cap259.91M Forward P/E- EPS next Y-1.90 Insider Trans-6.56% Shs Float58.46M Perf Month-72.00%
Income-23.24M PEG- EPS next Q-0.71 Inst Own103.83% Short Float15.20% Perf Quarter-75.86%
Sales43.36M P/S5.99 EPS this Y-1873.92% Inst Trans-8.38% Short Ratio3.43 Perf Half Y-45.75%
Book/sh1.70 P/B2.45 EPS next Y35.75% ROA-7.85% Short Interest8.89M Perf Year-18.63%
Cash/sh2.94 P/C1.41 EPS next 5Y- ROE-21.58% 52W Range3.14 - 21.88 Perf YTD-56.86%
Dividend Est.- P/FCF- EPS past 5Y48.88% ROI-17.08% 52W High-81.03% Beta1.98
Dividend TTM- Quick Ratio3.61 Sales past 5Y15.77% Gross Margin64.67% 52W Low32.17% ATR (14)1.05
Dividend Ex-Date- Current Ratio3.63 EPS Y/Y TTM75.19% Oper. Margin-423.39% RSI (14)24.76 Volatility9.35% 12.76%
Employees339 Debt/Eq0.32 Sales Y/Y TTM-73.78% Profit Margin-53.60% Recom1.75 Target Price10.80
Option/ShortYes / Yes LT Debt/Eq0.28 EPS Q/Q-36.25% Payout- Rel Volume0.46 Prev Close4.34
Sales Surprise-38.74% EPS Surprise-30.72% Sales Q/Q-62.83% EarningsMay 09 AMC Avg Volume2.59M Price4.15
SMA20-52.85% SMA50-68.13% SMA200-59.47% Trades Volume423,325 Change-4.38%
Date Action Analyst Rating Change Price Target Change
May-10-24Downgrade TD Cowen Buy → Hold
May-10-24Downgrade Stifel Buy → Hold $29 → $7
May-10-24Downgrade BMO Capital Markets Outperform → Market Perform $24 → $8
Apr-26-24Initiated B. Riley Securities Buy $25
Apr-09-24Upgrade TD Cowen Hold → Buy
Mar-04-24Reiterated BTIG Research Buy $12 → $24
Feb-14-24Downgrade H.C. Wainwright Buy → Neutral $12 → $14
Dec-20-23Upgrade Citigroup Neutral → Buy $7 → $13
Nov-07-23Upgrade Guggenheim Neutral → Buy $12
Mar-17-23Downgrade Guggenheim Buy → Neutral
May-25-24 12:00PM
May-17-24 12:50PM
May-16-24 12:59PM
May-13-24 12:30PM
07:30AM
06:01PM Loading…
May-10-24 06:01PM
04:51PM
03:29PM
03:17PM
02:01PM
08:35AM
07:48AM
07:30AM
07:15AM
07:14AM
07:12AM Loading…
07:12AM
07:12AM
06:02AM
04:57AM
02:15AM
May-09-24 08:57PM
04:10PM
04:01PM
May-03-24 07:30AM
May-01-24 10:05AM
Apr-26-24 08:00AM
Apr-03-24 04:30PM
Mar-14-24 08:18AM
Mar-09-24 01:09PM
Mar-08-24 07:19AM
12:30AM Loading…
12:30AM
Mar-07-24 10:42PM
09:55PM
05:30PM
04:01PM
Mar-06-24 11:29PM
Mar-01-24 05:48PM
Feb-29-24 10:00AM
Feb-27-24 05:45PM
Feb-02-24 04:30PM
07:19AM
Jan-15-24 04:51PM
Jan-08-24 04:30PM
Dec-17-23 12:03PM
Nov-07-23 10:56AM
08:59AM
01:15AM
Nov-06-23 05:12PM
04:27PM
04:01PM
Nov-02-23 04:30PM
Oct-31-23 04:30PM
Sep-05-23 07:00AM
Aug-31-23 04:30PM
Aug-19-23 07:40AM
Aug-14-23 11:19AM
Aug-11-23 01:26PM
Aug-10-23 12:33PM
07:01AM
Aug-09-23 11:30PM
05:50PM
04:52PM
04:01PM
Jul-31-23 05:35PM
Jul-05-23 11:55AM
Jun-28-23 08:12AM
Jun-08-23 07:27AM
May-14-23 08:09AM
May-10-23 12:10PM
12:30AM
May-09-23 05:25PM
04:21PM
04:01PM
May-05-23 08:27AM
May-04-23 04:30PM
Apr-25-23 10:01AM
Apr-24-23 06:15PM
Apr-07-23 08:48AM
Mar-22-23 01:22PM
Mar-20-23 06:59PM
Mar-18-23 02:52AM
Mar-17-23 06:15PM
Mar-16-23 12:17PM
07:10AM
Mar-15-23 11:00PM
05:35PM
04:01PM
Mar-14-23 12:32PM
08:00AM
Mar-11-23 07:30AM
Mar-09-23 03:59PM
Mar-08-23 05:36PM
Mar-07-23 06:00PM
Mar-02-23 04:30PM
Feb-20-23 09:56AM
Feb-17-23 06:27AM
Feb-14-23 10:01AM
Feb-13-23 05:20PM
Feb-06-23 04:30PM
Jan-24-23 07:57AM
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
STUMP DAVID CDirectorMay 20 '24Option Exercise0.004,50004,500May 22 04:33 PM
Jackson Scott ThomasDirectorMay 20 '24Option Exercise0.004,50004,500May 22 04:34 PM
HEIDEN WILLIAM KDirectorMay 20 '24Option Exercise0.004,50004,500May 22 04:34 PM
SIEGEL JAY PHILIPDirectorMay 20 '24Option Exercise0.004,50004,500May 22 04:34 PM
HURWITZ EDWARDDirectorMay 20 '24Option Exercise0.004,500037,574May 22 04:32 PM
Ferrante Karen JeanDirectorMay 20 '24Option Exercise0.004,50004,500May 22 04:32 PM
Chhabra MeenuDirectorMay 20 '24Option Exercise0.004,50004,500May 22 04:33 PM
Liu MargaretDirectorMay 20 '24Option Exercise0.004,50004,500May 22 04:33 PM
O'Brien Federica F.DirectorMay 20 '24Option Exercise0.004,50004,500May 22 04:33 PM
Peters Jeffrey StuartSenior VP and General CounselApr 04 '24Option Exercise4.8242,500204,85051,395Apr 08 06:07 PM
Peters Jeffrey StuartSenior VP and General CounselApr 04 '24Sale15.5551,395799,1480Apr 08 06:07 PM
Peters Jeffrey StuartSenior VP and General CounselMar 06 '24Option Exercise10.9019,625213,87528,520Mar 08 04:14 PM
Peters Jeffrey StuartSenior VP and General CounselMar 06 '24Sale21.5019,625421,9388,895Mar 08 04:14 PM
Risser Eric BlasiusChief Operating OfficerMar 04 '24Option Exercise10.1515,000152,25080,059Mar 06 04:20 PM
Spitznagel ThomasSr VP, Technical OpsMar 04 '24Option Exercise11.5010,000115,00018,316Mar 06 04:19 PM
Risser Eric BlasiusChief Operating OfficerMar 04 '24Sale19.7641,159813,50138,900Mar 06 04:20 PM
Karrels JamesSVP, CFO and SecretaryMar 04 '24Sale20.5030,000615,000171,452Mar 06 04:18 PM
Spitznagel ThomasSr VP, Technical OpsMar 04 '24Sale20.0010,000200,0008,316Mar 06 04:19 PM
Peters Jeffrey StuartSenior VP and General CounselFeb 26 '24Sale17.2216,124277,6558,895Feb 28 04:20 PM
Peters Jeffrey StuartSenior VP and General CounselFeb 22 '24Option Exercise0.0026,250035,145Feb 26 04:27 PM
Bonvini EzioSr VP, Research & CSOFeb 22 '24Option Exercise0.0028,1250110,258Feb 26 04:26 PM
Bonvini EzioSr VP, Research & CSOFeb 15 '24Option Exercise0.0016,670088,004Feb 20 06:03 PM
Risser Eric BlasiusChief Operating OfficerFeb 15 '24Option Exercise0.0016,670070,938Feb 20 06:04 PM
Cilinski LynnVP, Controller and TreasurerFeb 15 '24Option Exercise0.006,66808,591Feb 20 06:04 PM
Koenig ScottPresident and CEOFeb 15 '24Option Exercise0.0042,34101,091,977Feb 20 06:04 PM
Peters Jeffrey StuartSenior VP and General CounselFeb 15 '24Option Exercise0.0013,336013,336Feb 20 06:05 PM
Spitznagel ThomasSr VP, Technical OpsFeb 15 '24Option Exercise0.0013,336013,336Feb 20 06:03 PM
Karrels JamesSVP, CFO and SecretaryFeb 15 '24Option Exercise0.0015,0030206,779Feb 20 06:04 PM
Eck Stephen L.Chief Medical OfficerFeb 15 '24Option Exercise0.0016,670016,670Feb 20 06:41 PM
Bonvini EzioSr VP, Research & CSOFeb 07 '24Sale18.003,33460,01271,334Feb 07 04:19 PM
Peters Jeffrey StuartSenior VP and General CounselFeb 05 '24Option Exercise11.1176,251847,35576,251Feb 07 04:17 PM
Peters Jeffrey StuartSenior VP and General CounselFeb 05 '24Sale16.5076,2511,258,1420Feb 07 04:17 PM
Bonvini EzioSr VP, Research & CSOFeb 01 '24Sale15.0013,316199,74074,668Feb 02 04:21 PM
Bonvini EzioSr VP, Research & CSOJan 19 '24Sale12.0013,316159,79287,984Jan 22 04:57 PM
Bonvini EzioSr VP, Research & CSODec 20 '23Sale10.0818,880190,310101,300Dec 21 04:12 PM
BIOTECH TARGET N V10% OwnerOct 02 '23Buy4.46150,000669,5859,929,963Oct 04 03:31 PM
BIOTECH TARGET N V10% OwnerSep 07 '23Buy5.26200,0001,052,8409,779,963Sep 11 03:39 PM
HURWITZ EDWARDDirectorAug 30 '23Buy4.9115,00073,65033,074Sep 01 04:06 PM